Dysfunction of epithelial permeability barrier induced by HMGB1 in 2.5D cultures of human epithelial cells

Tissue Barriers. 2022 Apr 3;10(2):1972760. doi: 10.1080/21688370.2021.1972760. Epub 2021 Sep 18.

Abstract

Airway and intestinal epithelial permeability barriers are crucial in epithelial homeostasis. High mobility group box 1 (HMGB1), increased by various stimuli, is involved in the induction of airway inflammation, as well as the pathogenesis of inflammatory bowel disease. HMGB1 enhances epithelial hyperpermeability. Two-and-a-half dimensional (2.5D) culture assays are experimentally convenient and induce cells to form a more physiological tissue architecture than 2D culture assays for molecular transfer mechanism analysis. In 2.5D culture, treatment with HMGB1 induced permeability of FITC-dextran into the lumen formed by human lung, nasal and intestinal epithelial cells. The tricellular tight junction molecule angulin-1/LSR is responsible for the epithelial permeability barrier at tricellular contacts and contributes to various human airway and intestinal inflammatory diseases. In this review, we indicate the mechanisms including angulin-1/LSR and multiple signaling in dysfunction of the epithelial permeability barrier induced by HMGB1 in 2.5D culture of human airway and intestinal epithelial cells.

Keywords: 2.5d matrigel cultures; EW-7197; PF431396; PYK2; TGF-β; angulin-1/LSR; cell metabolism; claudins; epithelial permeability barriers; hmgb1; human intestinal epithelial cell line CACO-2; normal human nasal epithelial cells; normal human pulmonary epithelial cells; p63; proinflammatory cytokines; tight junctions; tnfα-antibody; tricellulin.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Epithelial Cells / metabolism
  • HMGB1 Protein* / metabolism
  • Humans
  • Permeability
  • Signal Transduction
  • Tight Junctions / metabolism

Substances

  • HMGB1 Protein

Grants and funding

This work was supported by JSPS KAKENHI [Grant Numbers 19K07464 and 20K17186] and GSK Japan Research 2019 (Konno T).